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In tumor growth, angiogenesis, the process of new-formation of blood vessels from pre-existing ones, is uncontrolled and
unlimited in time. The vascular phase is characterized by the new-formation of vascular channels that enhances tumor cell
proliferation, local invasion and hematogenous metastasis. Human malignant melanoma is a highly metastatic tumor with poor
prognosis, and high resistance to treatment. Parallel with progression, melanoma acquires a rich vascular network, whereas an
increasing number of tumor cells express the laminin receptor, which enables their adhesion to the vascular wall, favouring
tumor cell extravasation and metastases. Melanoma neovascularization has been correlated with poor prognosis, overall survival,
ulceration and increased rate of relapse. Secretion of various angiogenic cytokines, i.e. VEGF-A, FGF-2, PGF-1 and -2, IL-8, and
TGF-1 by melanoma cells promote the angiogenic switch and has been correlated to transition from the radial to the vertical
growthphase,andtothemetastaticphase.Moreover,melanomacellsoverexpressαvβ3,αvβ5,α2β1andα5β1integrinsandrelease,
together with stromal cells, higher amount of metalloproteases that increasing their invasive potential and angiogenesis. Basing on
these observations, diﬀerent molecular targets of antiangiogenic molecules has be recognized and various antiangiogenic agents
are currently in preclinical and clinical trials for melanoma.
1.Introduction
Angiogenesis, the process of new formation of blood vessels
from preexisting ones, takes place in both physiological
and pathological conditions, such as chronic inﬂamma-
tion and cancer [1, 2]. In tumor growth, angiogenesis is
uncontrolled and unlimited in time and it is involved in
the transition from the avascular to the vascular phase
[3], the so-called angiogenic switch, in which the balance
between angiogenesis inducers and inhibitors leans towards
the former [4]. The vascular phase is characterized by
the new formation of vascular channels that enhance
tumor cell proliferation, local invasion, and hematogenous
metastasis.
2. AngiogenesisinHumanMelanoma
Human malignant melanoma is a highly metastatic tumor
with poor prognosis and high resistance to treatment.
It progresses through diﬀerent steps: nevocellular nevi,
dysplastic nevi (when these two entity can be identiﬁed as
primary events in melanocytic neoplasia progression), in
situ melanoma, radial growth phase melanoma (Breslow
index ≤0.75mm), vertical growth phase melanoma (index
>0.75mm), and metastatic melanoma [5]. Primary tumor
grows horizontally through the epidermis; over time, a
vertical growth phase component intervenes and melanoma
increasesitsthicknessandinvadesthedermis.Onceavertical
growth phase has developed, there is a direct correlation
between the tumor thickness and the number of metastases
[6].
Parallel with progression, melanoma acquires a rich vas-
cular network, whereas an increasing number of tumor cells
express the laminin receptor, which enables their adhesion
to the vascular wall, favouring tumor cell extravasation and
metastases [7–9]. Melanoma neovascularization has been
correlated with poor prognosis, overall survival, ulceration,
and increased rate of relapse [10–12].2 Dermatology Research and Practice
3. The Role of AngiogenicCytokines
Secretion of vascular endothelial growth factor-A (VEGF-
A) by melanoma cells has been correlated to the transition
from the radial to the vertical growth phase, and to the
metastatic phase [13–15]. Ribatti et al. [12]h a v ed e m o n -
strated that increased microvascular density, strong VEGF-
A tumor immunoreactivity, increased vascular diameter,
and high number of vascular pillars—expression of the
intussusceptive microvascular growth—are correlated to a
high Breslow index (>3.6mm). Salven et al. [15]h a v e
demonstrated that up-regulation of VEGF-A expression in
metastatic melanoma is associated with an increase in the
number of tumor-inﬁltrating inﬂammatory cells expressing
VEGF-A. Finally, melanotransferrin, which is angiogenic in
vitro and in vivo, is overexpressed in human melanoma and
correlates to the tumor VEGF-A expression and progression
[16].
Fibroblast growth factor-2 (FGF-2) is overexpressed in
human melanoma and may be induced by an increased
release by tumor cells of matrix metalloproteinases (MMPs)
which, in turn, degrade extracellular matrix inducing the
release of FGF-2 stored there as an inactive form. Ribatti et
al. [17] have demonstrated a signiﬁcant correlation between
melanoma progression, percentage of FGF-2-expressing
tumor cells, and the number of mast cells which, in turn,
secrete other angiogenic molecules, such as VEGF-A [15].
Anotherimportantstimulatorofmelanomaangiogenesis
is placental growth factor (PGF). PGF-1 and -2 are expressed
by melanoma cells and known to bind neuropilin-1 and -
2 receptors expressed on endothelial cells [18]. In addition,
PGF acts through binding to VEGF receptor-1 inducing the
mobilization and recruitment of VEGFR-1+ hematopoietic
precursors from bone marrow and enhancing blood vessel
maturation by acting on VEGFR-1-expressing smooth mus-
cle cells/pericytes [19]. Moreover, PGF forms heterodimers
with VEGF-A and enhances melanoma angiogenesis by
activating VEGFR-2 on endothelial cells [19, 20].
Interleukin-8 (IL-8) expression was found to be very
little in normal epidermis and benign melanocytic lesions.
However, it is dramatically increased in a majority of
cutaneous melanomas. Its serum levels in patients are
signiﬁcantly elevated compared to healthy individuals and
correlate with advanced disease stage as well as with overall
survival [21]. Melanoma-derived IL-8 is able to induce
endothelial cell migration, modulate vascular permeability,
and enhance actin stress ﬁber formation. These activities
resulted in enhanced angiogenesis, rapid tumor growth, and
increased metastatic potential [22, 23]. Liu et al. [24]h a v e
demonstrated that transforming growth factor-1 (TGF-1)
is able to enhance expression of IL-8 in human melanoma
cells and promote angiogenesis in several mouse xenograft
models.
4.IntegrinSignalingand
ExtracellularMatrixEnzymes
Vacca et al. [7, 9] have demonstrated that melanoma
cells express the 67-kDa laminin receptor in step with the
progression from the nevocellular to the dysplastic nevi, and
from the primary to the metastatic tumor. This expression
enables melanoma cell adhesion to the vascular wall and
together with the increased vascular network favors tumor
cell extravasation and metastasis.
Overexpression of αvβ3, αvβ5, α2β1, and α5β1 integrins
has been correlated with the transition from primary to
metastatic melanoma [25]. In turn, integrins overexpression
stimulates MMP-2 and MMP-7 in melanoma cells, increas-
ing their invasive potential [26].
Melanoma and tumor stromal cells express several
MMPs, including MMP-1, -2, -3, -7, -9, -14, -15, -16, as well
as tissue inhibitors of MMPs such as TIMP-1, -2, and -3 [27].
MMPs overexpression has been correlated with increased
microvasculardensity,Bcl-2overexpression,andlowsurvival
rate. The most extensively studied MMPs in melanomas
are MMP-2 and MMP-9. The expression and activation
of both enzymes have been correlated to the invasive and
metastatic phenotypes of the tumors [27–31] in which they
areconstitutivelyexpressedandhighlyassociatedwithatypia
and dediﬀerentiation into melanocytic lesions [28]. MMP-2
expression was highly correlated with the metastatic spread
and low survival rates [27]. Moreover, functional activity of
MMPs is required for tumor progression. Overexpression of
MT1-MMP in melanoma cells induced activation of MMP-2
which is crucial for extracellular matrix degradation. MMP-
2 and MT1-MMP+ tumor cells were often restricted to
the interface between the tumor invasive part and stroma
[32, 33]. Expression of MMPs is not restricted to tumor
cells but is also found abundantly in stromal cells indicating
a major contribution of host-derived proteases to tumor
progression [34]. Also MMP-1 expression is highly associ-
ated with melanoma progression [29]. MMP-9 expression in
melanoma cells was found exclusively during the horizontal
growth phase but not during the vertical phase. This clearly
suggests that expression of MMP-9 is an early event in
melanoma progression [28].
Several studies using either cell lines or animal models
have demonstrated that the balance between MMPs and
their inhibitors (TIMPs) ﬁnally determines melanoma pro-
gression [33–39]. Overexpression of TIMP-1, -2, and -3
signiﬁcantly reduces melanoma tumor cell invasion, migra-
tion, growth and metastasis, and signiﬁcantly reduces tumor
neovascularization in the several tumor models studied [40].
Urokinase plasminogen activator and its receptor
(uPA/uPAR) have been demonstrated to play a crucial role
in several stages of melanoma progression including tumor
cell migration, invasion, and metastasis. uPA secreted from
melanoma cells is able to regulate endothelial cell functions
including migration and the organization of endothelial cells
into tube-like structures [41–43].
The extracellular matrix enzymes and their inhibitors
play also an important role in cancer dysregulated angio-
genesis [44, 45]. These enzymes are the major degrading
enzymes produced by angiogenic endothelial cells for migra-
tion trough extracellular matrix during neovessel formation
[46]. Moreover, MMPs and TIMPs may act as regulators
of signaling pathways through the cleavage of nonmatrix
substrates, including cytokines, chemokines, and growthDermatology Research and Practice 3
Table 1: Molecular targets of antiangiogenic drugs.
Category Molecular Targets Name
Angiogenic growth factors and their receptors
VEGF Bevacizumab
Tyrosine kinase receptors Sorafenib
VEGF receptors PTK/ZK
DC101
Receptors for extracellular matrix, integrins
Integrin αvβ3 Vitaxin (MEDI-52)
αvβ3/αvβ5 Cilengitide
(EMD 121974)
Components of extracellular matrix and proteases
MMPs Batimastat
Marimastat
Extracellular matrix Endostatin
Complex mechanism of action
Angiogenesis inhibitors
and immunomodulators
Thalidomide
Lenalidomide
Cyclooxygenase-2 Celecoxib
factors. In the last ﬁfteen years, diﬀerent extracellular matrix
proteins and cleavage products have been identiﬁed. These
molecules possess the ability to regulate vascular develop-
ment, repair and function. Therefore, possible regulatory
mechanisms in vascular biology controlled by diﬀerent
cleavage products of basement membrane proteins (e.g.,
endostatin and tumstatin, endorepellin), their activation by
proteases and inhibitors, such as matrix metalloproteases
(MMPs), cathepsins, tissue inhibitors of MMPs and cystatin,
will be reviewed [47].
5. Antiangiogenic Therapies
As it is shown on Table 1,d i ﬀerent molecular targets of an-
tiangiogenic molecules can be recognized, so various antian-
giogenic agents are currently in clinical trials for melanoma.
Thalidomide has been found to have antiangiogenesis
and antiinﬂammatory properties, and accordingly it has
been used as a therapeutic agent in some malignant
tumors including liver, renal cell, and breast carcinomas
[48]. Thalidomide inhibits vasculogenic mimicry channel
and mosaic vessels formation in melanoma through the
regulation of vasculogenic factors, and it can induce necrosis
of tumor cells, which may be related with the NF-kappaB
signaling pathway [49, 50]. Many studies are also focused
on the eﬀects of thalidomide on advanced melanoma alone
[51, 52] or in combination with Interferon alpha 2b [53,
54], temozolomide [55, 56], and dacarbazine [57]w i t h
encouraging results.
On the basis of preclinical ﬁndings indicating that con-
tinuous low dose (metronomic) chemotherapy is thought to
inhibit tumor angiogenesis, [58] the evaluation of antian-
giogenic potency of various chemotherapeutic drugs for
metronomic chemotherapy, particularly taxol, is ongoing for
its eﬃcacy.
Semaxanib, a small molecule inhibitor of the VEGFR-2
tyrosine kinase, has shown encouraging results in patients
with metastatic melanoma [59, 60] in whom it has also
been evaluated in combination with thalidomide to assess
the eﬃcacy, tolerability, pharmacokinetic, and pharmacody-
namic characteristics [61]. The results of this last study have
demonstrated that the combination semaxanib-thalidomide
is feasible and demonstrated antitumor activity in patients
with metastatic melanoma who had failed prior therapy.
Another way to inhibit angiogenesis is the inhibition
of matrix metalloproteinase (MMP) activity. In the early
1990, MMP inhibitors generated great enthusiasm among
severalresearchgroups wishing to take them to clinical trials.
Preclinical trials of MMP inhibitors were very promising,
showing minimum side eﬀects compared to other drugs
available at the time. Several current inhibitors, which
have been tested in preclinical and clinical trials, are
broad category MMP inhibitors [62–64]. Pharmacological
inhibitors such as prinomastat, batimastat, and its analog
marimastat, which interfere with the catalytic site of the
MMPs, were the ﬁrst inhibitors studied in detail. Most of
the inhibitors tested in clinical trials were not very promising
due to the lack of positive outcomes and the appearance
of substantial drug side eﬀects, which were not observed
in preclinical studies. Therefore, most of the inhibitor
clinical trials were terminated following phase 3 clinical trials
[63, 64].
Good therapeutic eﬀects have been obtained in little
studies with the combination of bevacizumab (the anti-
VEGFmonoclonalantibody)andchemotherapyinadvanced
melanoma [65–68]. Moreover, preclinical data strongly sup-
port the use of a combination of bevacizumab and erlotinib,
a tyrosine kinase receptors inhibitor [67].
PI-88, a potent inhibitor of heparanase, demonstrates an
overall survival and time to progression similar to standard
chemotherapy [69].
Preclinical data suggest that the ectopic expression of
alphaIIb beta3 in melanoma cells can be exploited as a novel
target of antibody therapy [70].
Although most of these study have obtained encouraging
results, further evaluations of therapeutic strategies that
target multiple angiogenesis pathways may be warranted in
patients with advanced melanoma and other malignancies.4 Dermatology Research and Practice
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Finally, antiangiogenesis therapy might have the unin-
tended eﬀect of promoting tumor metastasis by increasing
vasculogenic mimicry as an alternative circulatory system
[71]. When the endothelium-dependent vessels are inhib-
ited by the eﬀective angiogenesis inhibitors, the hypoxia
of tumor cells caused by antiangiogenesis may increase
vasculogenic mimicry compensatively which can replace the
job of endothelium-dependent vessels to maintain the tumor
blood supply and provide a convenient route of tumor
metastasis. As a result, antiangiogenesis therapy might have
the unintended eﬀect of promoting tumor metastasis by
increasing vasculogenic mimicry.
6. Concluding Remarks
Angiogenesis in melanoma is crucial for tumor progression
and metastasic escape. Since this process involves a syner-
gistic action of several classes of angiogenic molecules and
signaling pathways (Figure 1), several possibilities exist for
the development of antiangiogenic therapeutic strategies.
Numerous angiostatic compounds are already in clinical
trials, but these approaches should be further developed.
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